Sector News

Teva restructuring puts R&D programs on the chopping block

December 15, 2017
Life sciences

Teva Pharmaceutical has unveiled its restructuring plan—and it doesn’t look good for R&D.

The plan will address a number of key areas, including the closure or divestment of R&D sites, as well as an evaluation of the company’s R&D programs, CEO Kåre Schultz said in a letter to employees.

It is expected to affect a “significant number” of R&D facilities and other sites, Schultz said. Teva will also conduct a “thorough review of all R&D programs across the entire company,” with an eye on prioritizing core projects and dumping others, while somehow “maintaining a substantial pipeline.”

All told, the plan will lead to 14,000 layoffs, about 25% of Teva’s total workforce. Slated to start in 2018, the company will begin notifying affected employees over the next three months. Schultz did not detail the distribution of the job cuts, saying that “all businesses and regions will be affected.”

Israeli Prime Minister Benjamin Netanyahu has asked Schultz to limit the layoffs in Israel to a minimum, Reuters reported.

With the restructuring, Teva aims to pare down costs, streamline the organization and boost business performance, profitability, cash flow generation and productivity, Schultz said. The company has had to downsize its guidance again and again thanks to generics pricing pressure and a pile of dealmaking debt.

“These are decisions I don’t take lightly but they are necessary to secure Teva’s future. We will implement these changes with fairness and the utmost respect for our colleagues worldwide,” he said.

The two-year plan aims to cut Teva’s costs by $3 billion by the end of 2019, from an estimated cost base of $16.1 billion for 2017. But the restructuring itself will end up costing the company at least $700 million in 2018, according to a statement. And the price tag could be even higher, depending on how many manufacturing plants, R&D sites and other office locations the company decides to shut or sell.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach